Rocket (RCKT) news
Recent news
Premarketing: Woodward/Pimco $548M+ RCKT 2026-CES10 RMBS
Premarketing activity has recently intensified around the Woodward/Pimco $548 million+ RCKT 2026-CES10 RMBS offering, as market participants assess the structure and potential performance of the transaction. The deal, which is set to close in the coming months, is being marketed as a residential…
AInvest Wire · 6d agoRocket Pharmaceuticals highlights FDA-aligned pivotal phase 2 trial and updated clinical findings for RP-A501 following Danon disease investor webinar
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced continued alignment with the U.S. Food and Drug Administration (FDA) on key aspects of its global pivotal Phase 2 trial for RP-A501, a gene therapy candidate for the treatment of Danon disease. The FDA has confirmed the recalibrated dose of…
AInvest Wire · Oct 7, 2026Rocket Pharmaceuticals, Inc.: Jefferies cuts target price to $2.95 from $4.25
Jefferies Group has revised its price target for Rocket Pharmaceuticals, Inc. (RCKT) to $2.95 from $4.25, reflecting a significant downgrade in its outlook for the stock. The adjustment comes amid ongoing market volatility and a 21.07% year-to-date decline in RCKT’s share price. The firm’s decision…
AInvest Wire · Oct 7, 2026Rocket Pharma to fund Danon phase 2 with proceeds
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has outlined its financial strategy to support the continuation of its pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The company has secured alignment with the U.S. Food and Drug Administration (FDA) on key elements of the trial,…
AInvest Wire · Oct 6, 2026Rocket Pharmaceuticals announces closing of sale of rare pediatric disease priority review voucher for $180 million
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million, providing non-dilutive capital to support its cardiovascular gene therapy pipeline. The PRV was awarded following the FDA’s accelerated approval of…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.